placeholder newsslider

Basel Series of Special Interest Focus Groups

„Outcome Measures of New Technologies in Uveal Melanoma”

in collaboration with the European Ocular Oncology Group and the International Society of Ocular Oncology

Date March 15th – 16th, 2021
Organizer European Vision Institute EEIG, Brussels, Belgium
Venue: Virtual, organized by the
Institute of Molecular and Clinical Ophthalmology Basel (IOB),
University of Basel, Mittlere Strasse 91, 4056 Basel, Switzerland


An interdisciplinary dialogue organised by the European Vision Institute in collaboration with the European Ocular Oncology Group and the International Society of Ocular Oncology

Rational management of patients with uveal melanoma must be based on evidence from research and quality evaluation. Such investigations require meaningful outcomes, which need to be clearly defined and measured in a standardised manner. Outcomes must be assessed according to relevant risk factors, which also need to be defined and measured adequately.

For these reasons, the European Vision Institute has organised this special-interest symposium, which will focus on outcomes in patients with uveal melanoma and new techniques for measuring these and interpreting results according to important predictors. This virtual symposium should be useful to all who are planning clinical research and quality evaluations in this field.

The proceedings of this meeting will be published in Ophthalmic Research.


last updated: 2021-03-11

Day 1 - March 15th, 2021

All times are UTC+1 = CET

15:00 – 15.10 Welcome and Introduction
Martine Jager & Hendrik Scholl
15:10 – 15:50 Cancer predisposition syndrome - detection of germline BAP1 in patients with UM, and detection of other tumors
15.10 –15.20 Tero Kivelä, University of Helsinki, FI : Characteristics of BAP1 families and functional testing.
15.20 –15.30 Cindy Chau, LUMC, Leiden, NL: Criteria for genetic testing and follow-up.
15.30 –15.50 Discussion
15:50 – 16:30 Diagnosis of a nevus vs melanoma, OCT
15:50 – 16:00 Bozena Romanowska-Dixon, Jagellonian University Krakow, PL: Characteristic differences in OCTs
16:00 – 16:10 Niels Brouwer, LUMC, Leiden, NL: OXYMAP and OCT-A of choroidal and iris tumors
16:10 – 16:30 Discussion
16:30 – 16:40 Coffee Break
16:40 – 17:20 Differentiating between nevi and melanoma
16:30 – 16:40 Bertil Damato, Oxford, UK: MOLES, a new algorithm to distinguish choroidal naevi from melanomas
16:40 – 16:50 Carol Shields, Philadelphia, USA: To find small ocular melanomas doing imaging.
16:50 – 17:00 Heinrich Heimann, Liverpool, UK: Biopsy of small choroidal tumours
17:00 – 17:20 Discussion
17:20 – 17:30 Quantitative MRI for diagnosis, treatment planning and follow-up of UM
Jan-Willen Beenakker, LUMC, Leiden, NL
17:30 – 17:50 Discussion

Day 2 - March 16th, 2021

All times are UTC+1 = CET

08:30 – 09:10 Prognostication of primary uveal melanoma
08:30 – 08:40 Sarah Coupland, Liverpool, UK: Histologic and genetic predictors of metastasis
08:40 – 08:50 Jens Kiilgaard, Copenhagen, DK: Algorithms combining genetic data and AJCC
08:50 – 09:10 Discussion
09:10 – 10.00 Outcomes after local treatment
09:10 – 09:20 Miltiadis Fiorentzis, Essen, DE: Predicting outcomes after ocular treatment.
09:20 – 09:30 Aline Riechardt, Berlin, DE: Evaluating local resection techniques
09:30 – 09:40 Gregor Willerding, Berlin, DE: Autofluorescence imaging for follow-up
09:40 – 09:50 Jens Heufelder, Berlin, DE: Requirements for proton beam therapy
09:50 – 10:10 Discussion
10:10 – 10:20 Coffee Break
10:20 – 11:00 Metastatic disease in UM
10:20 – 10:30 Elina Rantala, Helsinki, FI: Screening for metastatic disease
10:30 – 10:40 Sophie Piperno-Neumann, Paris, FR: Assessing treatment for metastatic disease
10:40 – 11:00 Discussion
11:00 – 11:40 Predicting metastatic death, and quality of life
11:00 – 11:10 Tero Kivelä, Helsinki, FI: Predicting metastatic death
11:20 – 11:30 Bertil Damato, London & Oxford; UK: Quality-of-life outcomes
11:30 – 11:50 Discussion
11:50 – 12:00 Summary and Farewell
(Martine Jager, Bertil Damato & Hendrik Scholl)

The European Vision Instititue EEIG was kindly supported by Roche

Publication in Preparation

Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting

in collaboration with the European Ocular Oncology Group and the International Society of Ocular Oncology

Jan-Willem Beenakkera, Niels Brouwera, Cindy Chaua, Sarah Couplandb, Miltiadis Fiorentzisc, Heinrich Heimannd, Jens Heufeldere, Antonia Joussenf, Jens Kiilgaardg, Tero Kiveläh, Sophie Piperno-Neumanni, Elina Rantalah, Bozena Romanowska-Dixon j, Carol Shieldsk, Gregor Willerdingl, Thomas Wheeler-Schillingm, n, Hendrik P. N. Schollo, p , Martine J. Jagera & Bertil Damatoq

a Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands, b University of Liverpool, Institute of Systems, Molecular and Integrative Biology, Crown Street, Liverpool L69 7BE, UK, c Universitätsklinikum Essen Klinik für Augenheilkunde, Hufelandstr. 55, 45147 Essen, Germany, d Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK, e Charité - Universitätsmedizin Berlin, Hahn-Meitner-Platz 1, 14109 Berlin, Germany, fCharité – Universitätsmedizin Berlin, Klinik für Augenheilkunde, Hindenburgdamm 30, 12200 Berlin, g Department of Ophthalmology, Rigshospitalet and Glostrup Hospital, Copenhagen University Hospital, Copenhagen, Denmark, h Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 4 C, Department of Ophthalmology, Helsinki, Finland, I Institut Curie, Department of medical oncology, 26, rue d'Ulm, 75005 Paris, France, j Klinika Okulistyki i Onkologii Okulistycznej, Uniwersytet Jagiellonski ul. Kopernika 38, Kraków, Poland,k  The Ocular Oncology Service, Wills Eye Hospital, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA,l DRK Kliniken Berlin Westend, Klinik für Augenheilkunde, Spandauer Damm 130, 14050 Berlin, Germany, mEuropean Vision Institute EEIG, Rue du Trône 98, 1050 Brussels, Belgium, nInstitute for Ophthalmic Research, Elfriede-Aulhorn-Strasse 7, 72076 Tübingen, Germany, o Department of Ophthalmology, University of Basel, Basel, Switzerland, p Institute of Molecular and Clinical Ophthalmology (IOB), Basel, Switzerland, q Nuffield Laboratory of Ophthalmology, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK.